×
About 3,570 results

ALLMedicine™ Hidradenitis Suppurativa Center

Research & Reviews  1,213 results

Anemia in Patients with Hidradenitis Suppurativa: Prevalence and Risk Factors in a Hosp...
https://www.ncbi.nlm.nih.gov/pubmed/35022114
Skinmed Jørgensen AR, Nielsen VW et. al.

Jan 14th, 2022 - We examined the prevalence and risk factors of anemia in patients with hidradenitis suppurativa (HS). The presence of anemia and information on risk factors was obtained through interview, clinical examination, and blood samples in a cohort of 367...

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
https://clinicaltrials.gov/ct2/show/NCT03713619

Jan 13th, 2022 - This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in approximately 541 patients with moderate to severe HS. The study consists of: screening (up to 4 weeks) treatment perio...

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04179175

Jan 13th, 2022 - This is a multicenter extension study to both core Phase III studies CAIN457M2301 and CAIN457M2302 (Core studies). This study contains a randomized withdrawal design, double blinded and placebo controlled up to Week 104 or loss of response. The su...

Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?
https://doi.org/10.1007/s40257-021-00667-8 10.1016/j.jaad.2021.01.059 10.1007/s40257-019-00439-5 10.1159/000515450 10.1002/14651858.CD010081.pub2 10.1111/ijd.15459 10.1111/bjd.19867 10.1016/j.jaad.2020.12.089 10.1016/j.jaad.2020.01.007
American Journal of Clinical Dermatology; Ghanian S, Yamanaka-Takaichi M et. al.

Jan 7th, 2022 - Hidradenitis suppurativa (HS) is a severe chronic relapsing inflammatory disorder of the hair follicle unit that can cause painful abscesses, nodules, tunnels, and tracts in intertriginous parts of the body. The disease can often result in disfigu...

Patient Impressions and Outcomes After Clinic-Based Hidradenitis Suppurativa Surgery.
https://doi.org/10.1001/jamadermatol.2021.4741
JAMA Dermatology; Ravi S, Miles JA et. al.

Jan 6th, 2022 - Surgical intervention is frequently needed to treat hidradenitis suppurativa (HS). Patient satisfaction is high based on previous studies, but reports of patient impressions of clinic-based operative experiences and postoperative recovery are limi...

see more →

Guidelines  1 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  45 results

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
https://clinicaltrials.gov/ct2/show/NCT03713619

Jan 13th, 2022 - This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in approximately 541 patients with moderate to severe HS. The study consists of: screening (up to 4 weeks) treatment perio...

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04179175

Jan 13th, 2022 - This is a multicenter extension study to both core Phase III studies CAIN457M2301 and CAIN457M2302 (Core studies). This study contains a randomized withdrawal design, double blinded and placebo controlled up to Week 104 or loss of response. The su...

Impact of Hidradenitis Suppurativa on Quality of Life Functions
https://clinicaltrials.gov/ct2/show/NCT03288337

Jan 6th, 2022 - The goal of this study is to get a better understanding of the impact of the skin condition, Hidradenitis Suppurativa, on quality of life function of patients. Patients with HS will be asked questions about demographics including gender, age, and ...

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT03926169

Jan 5th, 2022 - This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to ...

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
https://clinicaltrials.gov/ct2/show/NCT04414514

Jan 4th, 2022 - The primary efficacy measure is the proportion of participants that achieve HiSCR at Week 16 with topical ruxolitinib 1.5% cream as compared to Week 0. The HiSCR is defined as an at least a 50% reduction in the total abscess and inflammatory nodul...

see more →

News  161 results

Two questions can help establish a diagnosis of hidradenitis suppurativa
https://www.mdedge.com/dermatology/article/249228/medical-dermatology/two-questions-can-help-establish-diagnosis
Doug Brunk

Nov 30th, 2021 - According to Iltefat H. Hamzavi, MD, the initial clinical assessment for hidradenitis suppurativa (HS) includes posing two questions to patients: Have you had outbreaks of boils during the past 6 months? Where and how many boils have you had? Dr.

Management of Acute and Chronic Pain Associated With Hidradenitis Suppurativa: A Comprehensive Review of Pharmacologic and Therapeutic Considerations in Clinical Practice
https://www.mdedge.com/dermatology/article/248368/autoimmune-diseases/management-acute-and-chronic-pain-associated
George M. Jeha, MD, Vijay Kodumudi, BS et. al.

Nov 8th, 2021 - Hidradenitis suppurativa (HS) is a chronic inflammatory, androgen gland disorder characterized by recurrent rupture of the hair follicles with a vigorous inflammatory response. This response results in abscess formation and development of draining.

Treatment Stacking: Optimizing Therapeutic Regimens for Hidradenitis Suppurativa
https://www.mdedge.com/dermatology/article/247119/psoriasis/treatment-stacking-optimizing-therapeutic-regimens-hidradenitis
Terri Shih, BS, Vivian Shi, MD et. al.

Oct 6th, 2021 - Hidradenitis suppurativa (HS) is a debilitating chronic condition that often is recalcitrant to first-line treatments, and mechanisms underlying its pathology remain unclear. Existing data suggest a multifactorial etiology with different pathophys.

European Agency Recommends Two New Adalimumab Biosimilars
https://www.medscape.com/viewarticle/959002

Sep 17th, 2021 - The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization this week for two new adalimumab biosimilars, Hukyndra and Libmyris. The biosimilars, both developed by STADA Arzneimittel AG, will ...

Adalimumab Adds to Surgery Benefits for Hidradenitis Suppurativa
https://www.medpagetoday.com/dermatology/generaldermatology/94091

Aug 18th, 2021 - Adalimumab (Humira) in addition to surgery for moderate to severe hidradenitis suppurativa (HS) significantly increased the rate of complete response versus surgery alone, a first-ever randomized trial showed. After 12 weeks of preoperative treatm...

see more →

Patient Education  7 results see all →